Recombinant coagulation factors and thrombolytic agents

Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition

Volumn , Issue , 2016, Pages 293-307

  Modi, Nishit B ^a  

^a ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903799675     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (69)

1. Abildgaard CF, Simone JV, Corrigan JJ, et al. (1966). Treatment of hemophilia with glycine-precipitated Factor VIII. New Eng J Med 275:471-75.
2. Antonarakis SE, Youssoufian H, Kazazian Jr HH (1987). Molecular genetics of hemophilia A in man (Factor VIII deficiency). Mol Biol Med 4:81-94.
3. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators (1999). Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial. Lancet 354:716-22.
4. Baughman RA (1987). Pharmacokinetics of tissue plasminogen activator. In: Sobel B, Collen, D, Grossbard E, eds. Tissue Plasminogen Activator in Thrombolytic Therapy New York: Marcel Dekker, 41-53.
5. Benedict CR, Refino CJ, Keyt BA, et al. (1995). New variant of human tissue plasminogen activator (tPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human tPA. Circulation 92:3032-40.
6. Bennett WF (1983). Two forms of tissue-type plasminogen activator (tPA) differ at a single specific glycosylation site. Thromb Haemost 50:106.
7. Bleich SD, Adgey AAJ, McMechan SR, Love TW (1998). An angiographic assessment of alteplase: Double-bolus and front-loaded infusion regimens in myocardial infraction. Am Heart J 136:74-8.
8. Bu G, Maksymovitch EA, Schwartz AL (1993). Receptormediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells. J Biol Chem 268:13002-9.
9. Camani C, Gavin O, Bertossa C, Samatani E, Kruithof EK (1998). Studies on the effect of fucosylated and nonfucosylated finger/growth factor constructs on the clearance of tissue type plasminogen activator mediated by the low-density lipoprotein-receptor related protein. Eur J Biochem 251:804-11.
10. Cannon CP, Gibson CM, McCabe CH, et al. (1998). TNKtissue plasminogen activator compared with frontloaded alteplase in acute myocardial infarction. Circulation 98:2805-14.
11. Collen D, Stassen JM, Larsen GR (1988). Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 71:216-9.
12. The Continuous Infusion Versus Double-Bolus Administration of Alteplase (COBALT) Investigators (1997). A comparison of continuous infusion and alteplase with doublebolus administration for acute myocardial infarction. New Engl J Med 337:1124-30.
13. Eaton DL, Hass PE, Riddle L, et al. (1987). Characterization of recombinant human Factor VIII. J Biol Chem 262:3285-90.
14. Einarsson M, Brandt J, Kaplan L (1985). Large-scale purification of human tissue-type plasminogen activator using monoclonal antibodies. Biochim Biophys Acta 830:1-10.
15. Ferguson JJ (1999). Meeting highlight. Highlights of the 48th scientific sessions of the American College of Cardiology. Circulation 100:570-5.
16. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators (1993a). An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 329:673-82.
17. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators (1993b). The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. New Eng J Med 329:1615-22.
18. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators (1997). A comparison of reteplase with alteplase for acute myocardial infarction. New Engl J Med 337:1118-23.
19. Grünewald M, Müller M, Ellbrück D, et al. (1997). Double- versus single-bolus thrombolysis with reteplase for acute myocardial infarction: a pharmacokinetic and pharmacodynamic study. Fibrinol Proteol 11:137-45.
20. Harris RJ, Leonard CK, Guzzetta AW, Spellman MW (1991). Tissue plasminogen activator has an O-linked fucose attached to Threonine-61 in the epidermal growth factor domain. Biochemistry 30:2311-4.
21. Hedner U (1996). Dosing and monitoring NovoSeven® treatment. Haemostasis 216(Suppl 1):102-8.
22. Hansen L, Blue Y, Barone K, Collen D, Larsen GR (1988). Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator. J Biol Chem 263:15713-9.
23. Higgins DL, Bennett WF (1990). Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis. Annu Rev Pharmocol Toxicol 30:91-121.
24. Hironaka T, Furukawa K, Esmon PC, et al. (1992). Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 267:8012-20.
25. Hoffman M (2003) A cell-based model of coagulation and the role of factor VIIa. Blood Rev 17:S1-5.
26. Hoffman M, Monroe DM (2005). Rethinking the coagulation cascade. Current Hematol Rep 4:391-6.
27. Holvoet P, Boes J, Collen D (1987). Measurement of free, onechain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibody. Blood 69:284-9.
28. Hotchkiss A, Refino CJ, Leonard CK, et al. (1988). The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 60:255-61.
29. Hoyer LW (1981). The Factor VIII complex: Structure and function. Blood 58:1-13.
30. Jackson CM, Nemerson Y (1980). Blood coagulation. Ann Rev Biochem 49:767-811.
31. Keith JC, Ferranti, Misra B, et al. (1995). Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and dog. Thromb Haemost 73:101-5.
32. Kessler CM (2005). New perspectives in hemophilia treatment. Hematology. American Society of Hematology Education Program book, pp 429-35.
33. Keyt BA, Paoni NF, Refino CJ, et al. (1994). A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci (USA) 91:3670-4.
34. Kohnert U, Horsch B, Fischer S (1993). A variant of tissue plasminogen activator (t-PA) comprised of the kringle 2 and the protease domain shows a significant difference in the in vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed Chinese hamster ovary cells. Fibrinolysis 7:365-72.
35. Kostis JB, Dockens RC, Thadani U, et al. (2002). Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. Clin Pharmacokinet 41:445-52.
36. Lindley CM, Sawyer WT, Macik G, et al. (1994). Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55:638-48.
37. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and The Kogenate Previously Untreated Patient Study Group (1993). Recombinant Factor VIII for the treatment of previously untreated patients with hemophilia A. New Engl J Med 328:453-9.
38. Lusher J, Ingerslev J, Roberts H, Hedner U (1998a). Clinical experience with recombinant factor VIIa. Blood Coag Fibrinol 9:119-28.
39. Lusher JM, Roberts HR, Davignon G, et al. (1998b). A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in person with haemophilia A and B, with and without inhibitors. RFVII Study Group. Haemophilia, 4: 790-8.
40. Martin U, Sponer G, Strein K (1993). Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro. Blood Coag Fibrinolysis 4:235-42.
41. McCarthy KP, Timony GA, DeCoste MT, et al. (1995). Pharmacokinetics of recombinant factor IX in beagle dogs. Thromb Haemost 73:1016.
42. McCarthy KP, Brinkhous KM, Stewart PF, et al. (1997). The pharmacokinetics of fully γ-carboxylated factor IX and factor IX lacking γ-carboxylation at Glu-40 are similar in the hemophilia beagle dog. XVI Congress of the International Society of Thrombosis and Haemostasis, June 8-10, Florence, Italy.
43. McCluskey ER, Keyt BA, Refino CJ, et al. (1997). Biochemistry, pharmacology, and initial clinical experience with TNK-tPA in New therapeutic agents. In:Sasahara AA, Loscalzo, eds. Thrombosis and Thrombolysis.. New York: Marcel Dekker, 475-593.
44. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J (1988). The natural history of factor VIII:C inhibitors in patients with hemophilia A: a natural cooperative study. II. Observations on the initial development of factor VIII:C inhibitor. Blood 71:344-8.
45. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love T (1998). Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 79:134-9.
46. Modi NB, Fox NL, Clow F-W, et al. (2000). Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a Phase II study in patients with acute myocardial infarction. J Clin Pharmacol 40:508-15.
47. Pennica D, Holmes WE, Kohr WJ, et al.. (1983). Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Science 301:214-21.
48. Roddie PH, Ludlam CA (1997). Recombinant coagulation factors. Blood Rev 11:169-77.
49. Ross AM (1999). New plasminogen activators: A clinical review. Clin Cardiol 22:165-71.
50. Schaub R, Garzone P, Bouchard P, et al. (1998). Preclinical students of recombinant factor IX. Semin Hematol 2 (Suppl 2) 28-32.
51. Schwartz RS, Abildgaard CF, Aledort LM, et al. (1990). Human recombinant DNA-derived antihemophilic factor (Factor VIII) in the treatment of hemophilia A. New Engl J Med 323:1800-5.
52. Seifried E, Tanswell P, Ellbrück D, Haerer W, Schmidt A (1989). Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost 61:497-501.
53. Shapiro A, Gilchrist GS, Hoots WK, Gastineau DA (1988). Prospective randomized trial of two doses of rFVII (Novoseven) in hemophilic patients with inhibitors undergoing surgery. J Thromb Haemost 80:773-8.
54. Shapiro AD, Korth-Bradley J, Poon MC (2005). Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 11:571-82.
55. Spellman MW, Basa LJ, Leonard CK, et al. (1989). Carbohydrate structures of human tissue plasminogen activator expressed in Chinese Hamster Ovary cells. J Biol Chem 264:14100-111.
56. Tanswell P, Seifried E, Su Pcaf, Feuerer W, Rijken DC (1989). Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 46:155-62.
57. Tanswell P, Heinzel G, Greischel A, Krause J (1990). Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. J Pharmacol Exp Ther 255:318-24.
58. Tanswell P, Tebbe U, Neuhaus K-L, Gläsle-Schwarz L, Wojcik J, Seifried E (1992). Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 19:1071-5.
59. Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholz K-H, Herrmann KS (1989). Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 64:448-53.
60. Thim L, Bjoern S, Christensen M, et al. (1988) Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 27:7785-93.
61. Thomas GR, Thibodeaux H, Errett CJ, et al. (1994). A longhalf- life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 25:2072-8.
62. van Griensven JMT, Huisman LGM, Stuurman T, et al. (1996). Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. Clin Pharmacol Ther 60:504-11.
63. Vehar GA, Keyt BA, Eaton D, et al. (1984a). Structure of human Factor VIII. Nature 312:337-42.
64. Vehar GA, Kohr WJ, Bennett WF, et al. (1984b). Characterization studies on human melanoma cell tissue plasminogen activator. Bio/Tech 2:1051-7.
65. Vehar GA, Spellman MW, Keyt BA, et al. (1986). Characterization studies of human tissue-type plasminogen activator produced using recombinantDNAtechnology. Cold Spring Harbor Symp Quant Biol 51:551-62.
66. Verstraete M, Bernard R, Bory M, Brower RW, Collen D, et al. (1985). Randomized trial of intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for recombinant tissue-type plasminogen activator. Lancet 1:842.
67. Wang-Clow F, Fox NL, Cannon CP, et al. (2001). Determination of a weight-adjusted dose of TNKtissue plasminogen activator. Am Heart J 141:33-40.
68. White GC, Beeb A, Nielsen B (1997). Recombinant Factor IX. Thromb. Haemostasis 78:261-5.
69. White G, Shapiro A, Ragni M, et al. (1998). Clinical evaluation of recombinant factor IX. Semin Hematol 2(Suppl 2):33-8.